A Phase 2 Study Of UCN-01 In Advanced Renal Cell Carcinoma

University of California, San Francisco4 个研究点分布在 1 个国家开始时间: 2002年12月最近更新: 2014年1月6日

适应症

试验速览

阶段: 2 期
发起方: University of California, San Francisco
试验地点: 4

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of UCN-01 in treating patients who have unresectable stage III or stage IV kidney cancer.

详细描述

OBJECTIVES:

Determine the efficacy of UCN-01, in terms of time to objective progression, in patients with stage IV or unresectable stage III renal cell carcinoma.
Determine the objective response rate in patients treated with this drug.

OUTLINE: Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 21-61 patients will be accrued for this study within 15 months.

研究设计

研究类型: Interventional
主要目的: Treatment

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

University of California, San Francisco

申办方类型

Other

研究点 (4)

Loading locations...

相似试验

已完成

1 期

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian Cancer

NCT00045175University Health Network, Toronto33

已完成

1 期

UCN-01 in Treating Patients With Advanced CancerUnspecified Adult Solid Tumor, Protocol SpecificLymphomaLeukemia

NCT00003289Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

已完成

1 期

UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid TumorsUnspecified Adult Solid Tumor, Protocol Specific

NCT00006464City of Hope Medical Center

已完成

1 期

Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic LymphomaLymphomaLeukemia

NCT00045513University Health Network, Toronto

已完成

1 期

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic SyndromeMyelodysplastic SyndromesLeukemia

NCT00004263M.D. Anderson Cancer Center16